Rocket Pharmaceuticals, INC Form 4 insider transactions

Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 1,409 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

CEO of Rocket Pharmaceuticals, Gaurav Shah, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold 718 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Mikael Dolsten, a director at Rocket Pharmaceuticals, received 14,220 restricted stock units (RSUs) as part of a consulting agreement.

CEO Gaurav Shah recently purchased 20,000 shares of Rocket Pharmaceuticals at $5.08 per share, increasing his direct holdings.

Kinnari Patel, President, Head of R&D and COO of Rocket Pharmaceuticals, reports that her spouse purchased 21,099 shares of RCKT common stock in a series of brokered transactions.

Aaron Ondrey, CFO of Rocket Pharmaceuticals, sold 7,489 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Jonathan Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Kinnari Patel, President, Head of R&D and Chief Operating Officer of Rocket Pharmaceuticals, sold 6,078 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Martin Wilson, General Counsel of Rocket Pharmaceuticals, sold 3,222 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold shares to cover tax obligations related to vesting Restricted Stock Units.

Gaurav Shah, CEO of Rocket Pharmaceuticals, sold 16,303 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Martin Wilson, General Counsel of Rocket Pharmaceuticals, reports the acquisition of restricted stock units (RSUs) and stock options, as well as the disposal of common stock.

CEO Gaurav Shah reports acquiring shares and stock options in Rocket Pharmaceuticals, according to a Form 4 filing with the SEC.

Jonathan Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, reports the acquisition and disposal of common stock and stock options.

Kinnari Patel, a Rocket Pharmaceuticals executive, acquired shares and options in the company, as reported in a recent SEC filing.

Chief Financial Officer Aaron Ondrey of Rocket Pharmaceuticals reports acquisition of restricted stock units (RSUs) and stock options, along with the disposal of common stock.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer at Rocket Pharmaceuticals, acquired shares and options in the company on February 11, 2025.

Director Piratip Pratumsuwan acquired stock options for Rocket Pharmaceuticals shares, according to a recent SEC filing.

John Militello, a Vice President at Rocket Pharmaceuticals, sold 896 shares of common stock on January 23, 2025, to cover tax obligations related to vesting Restricted Stock Units.

RTW Investments, LP acquired pre-funded warrants for 400,000 shares of Rocket Pharmaceuticals common stock in a private placement.

A Rocket Pharmaceuticals executive sold 1,224 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

A Rocket Pharmaceuticals executive, Kinnari Patel, sold 4,588 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

Rocket Pharmaceuticals CEO, Gaurav Shah, sold 11,091 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

Rocket Pharmaceuticals' General Counsel, Martin Wilson, sold 1,175 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

Mark Andrew White, General Manager of Commercial Affairs at Rocket Pharmaceuticals, sold 3,080 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Director Elisabeth Bjork reports the acquisition of stock options for 607 shares of Rocket Pharmaceuticals common stock.

Director Gotham Makker reports the acquisition of stock options for Rocket Pharmaceuticals shares.

Director Mikael Dolsten reports acquisition of stock options in Rocket Pharmaceuticals, Inc.